Do you want to read an article? Please log in or register.
Clinical Features and Outcomes of Infants with Retinopathy of Prematurity Who Fail Anti-VEGF Therapy
Retinal Diseases
Related content
Retinal DiseasesFurther Publications
Real-world visual outcomes of laser and anti-VEGF treatments for retinopathy of prematurity
Am J Ophthalmol
Gundlach BS, Kokhanov A, Altendahl M, Suh SY, Fung S, Demer J, Pineles S, Khitri M, Chu A, Tsui I
doi: 10.1016/j.ajo.2021.11.015
Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology
Ophthalmology.
VanderVeen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR
doi: 10.1016/
Retinal Diseases
Anti-VEGF Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions
Am J Ophthalmol.
Wubben TJ, Johnson MW, Anti-VEGF Treatment Interruption Study Group
doi: 10.1016/j.ajo.2019.03.005.
Retinal Diseases
Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial
JAMA Pediatr.
Stahl A, Krohne TU, Eter N, Oberacher-Velten I, Guthoff R, Meltendorf S, Ehrt O, Aisenbrey S, Roider J, Gerding H, Jandeck C, Smith LEH, Walz JM; Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity (CARE-ROP) Study Group
doi: 10.1001/
Retinal Diseases
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial
Lancet.
Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, Li J, Liew M, Maier R, Zhu Q, Marlow N
doi: 10.1016/S0140-6736(19)31344-3.
Macular DiseasesRetinal Diseases
Long-term Visual Outcomes and Morphologic Biomarkers of Vision Loss in Eyes with Diabetic Macular Edema treated with Anti-VEGF Therapy
Am J Ophthalmol
Borrelli E, Grosso D, Barresi C, Lari G, Sacconi R, Senni C, Querques L, Bandello F, Querques G
doi: 10.1016/j.ajo.2021.09.002
Retinal DiseasesFurther Publications
Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF)
Prog Retin Eye Res
Tsai AS, Chou HD, Ling XC, Al-Khaled T, Valikodath N, Cole E, Yap VL, Chiang MF, Chan RVP, Wu WC
doi: 10.1016/j.preteyeres.2021.101018
COMMENTED
Retinal Diseases
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial
JAMA Ophthalmol.
Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, Bressler NM, Elman MJ, Ferris FL 3rd, Gardner TW, Jampol LM, Martin DF, Melia M, Stockdale CR, Beck RW, Diabetic Retinopathy Clinical Research Network
doi: 10.1001/jamaophthalmol.
RECOMMENDED
Retinal Diseases
Aggressive Posterior Retinopathy of Prematurity: Clinical and Quantitative Imaging Features in a Large North American Cohort
★ 3
Recommended by
Prof. Dr Ke Yao, Faculty Member
Ophthalmology.
Bellsmith KN, Brown J, Kim SJ, Goldstein IH, Coyner A, Ostmo S, Gupta K, Chan RVP, Kalpathy-Cramer J, Chiang MF, Campbell JP
doi: 10.1016/j.ophtha.2020.01.052.